The effectiveness of the ColoSense multitarget stool RNA test in detecting colorectal cancer (CRC) and advanced adenomas.
Key Findings:
- High Sensitivity for CRC Detection: The ColoSense test demonstrated a high sensitivity for detecting colorectal cancer, with a rate of 94%. For advanced adenomas, the sensitivity was 46%.
- Specificity for No Lesions: The specificity of the test for detecting no lesions on colonoscopy was 88%.
- CRC-PREVENT Trial: The findings are based on the prospective, cross-sectional phase 3 CRC-PREVENT trial, which enrolled 8,920 participants. The trial aimed to evaluate the sensitivity and specificity of the ColoSense test compared to colonoscopy.
- Noninvasive RNA-Based Test: Erica K. Barnell, MD, PhD, chief science officer and co-founder at Geneoscopy, highlighted the need for a convenient, noninvasive option for CRC screening, especially for average-risk individuals. The ColoSense test, being RNA-based, offers a noninvasive screening method.
- Effective in Younger Age Groups: The test showed significant improvement in sensitivity for CRC and advanced adenomas compared to the fecal immunochemical test (FIT). Notably, for participants aged 45 to 49 years, the sensitivity for CRC was 100%, and for advanced adenomas, it was 45%.
- Potential for Early Detection: The results suggest that the ColoSense test can effectively screen patients noninvasively in the 45 to 50 age range, offering a valuable option for early detection in this population.
The study demonstrates the potential of the ColoSense multitarget stool RNA test as an effective tool for early detection of colorectal cancer and advanced adenomas, particularly in younger individuals who are at average risk.